Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Bacteremia and Endocarditis September 26th, 2005 Blood Cultures 2 sets, >15 minutes apart Now continuous monitoring No entry of bacteria for monitoring lysis-centrifugation system (Isolator) used for either routine bacteria, fungi, mycobacteria, or fastidious organisms such as Bartonella or Brucella Labor intensive More contamination Technique 70% alcohol, followed by tincture of iodine (1 minute) or povidone iodine (2 minutes). septum of the culture bottle or tube need only be wiped with 70% alcohol transported to the laboratory promptly volume of blood cultured and the number of sets drawn are particularly important current recommendations for adults are to draw at least two separate blood cultures totaling 30 to 40 ml of blood. Separate venipunctures should be performed to help interpret cultures that contain skin flora Classification of Bacteremia Community-acquired Nosocomial Healthcare-associated Bacteremia indwelling catheters HD receiving other outpatient therapy Wound care nursing home residents Friedman: Ann Intern Med, Volume 137(10).November 19, 2002.791-797 Martin: N Engl J Med, Volume 348(16).April 17, 2003.1546-1554 Infectious Endocarditis (IE) Traditional risk factor of RHD decreasing, newer factors increasing Emergence of enterococci and Staph, particularly MRSA and VRE, also VISA and VRSA Viridans Strep now emerging MDR strains Subtypes native value IE prosthetic valve IE RHD MVP (10-100 fold increased risk if regurgitant) Degenerative/inherited valve disorders Early (Staph epi, Staph aureus) Late (Strep, HACEK) IE in intravenous drug users Healthcare-associated IE nosocomial IE Microbiologic Etiology in 1779 Patients With Definite Endocarditis From: Fowler: JAMA, Volume 293(24).June 22/29, 2005.3012–3021 Trends in Age- and Sex-Adjusted Incidence Rates of Infective Endocarditis Caused by Staphylococcus aureus and Viridans Group Streptococci From 1970 to 2000 in Olmsted County, Minnesota From: Tleyjeh: JAMA, Volume 293(24).June 22/29, 2005.3022–3028 IDU-associated IE median age 30 and 40 yrs up to 40% of cases of IE in San Francisco tricuspid valve > 50% of cases, aortic in 25%, mitral in 20%, mixed right- and left-sided IE unusual. injections of impure drugs and particulates might produce microtrauma to the tricuspid leaflets, facilitating microbial colonization 20–40% of IDU with IE have pre-existing cardiac lesions Bacteria often originate from the skin streptococci and others also seen Pseudomonas aeruginosa and fungi may produce severe IE. mortality of IE higher in patients who have AIDS Nosocomial IE The incidence is increasing. Many patients have other debilitating underlying < 50% had obvious cardiac predisposing factors In most circumstances a potential source of bacteremia could be identified, (lines, procedures) staphylococci and enterococci most common other organisms-Gram-negative bacteria and fungi. Right-sided IE is increasingly recognized in association with central venous lines, pulmonary artery catheters and pacemakers. procedures that produce transient bacteremia represent risk in hospitalized patients, especially when the circulating organism is S. aureus. mortality of nosocomial IE is greater than 50%. Culture-negative IE HACEK Haemophilus spp. Actinobacillus actinomycetemcomitans Cardiobacterium hominis Eikenella corrodens Kingella kingae Nutritionally-deficient Strep spp. Fastidious GNR Culture-negative IE Coxiella burnetii (Q fever) Brucella Bartonella quintana Chlamydia Tropheryma whippelii Pathogenesis Basic lesion is endothelial damage IE pathogens possess surface ligands that mediate attachment to extracellular matrix proteins of the host (MSCRAMMs) direct invasion of endothelial cells may also occur Transient bacteremias occur during chewing, toothbrushing and other normal activities, and from more invasive procedures Microscopic appearance of a vegetation from a patient suffering mitral valve infective endocarditis due to Streptococcus sanguis. The purple area represents clusters of streptococci packed within a fibrin-platelet meshwork. Professional phagocytes are essentially absent from the lesion. IE Prophylaxis Goals: No controlled studies Regimens used in humans are based upon their proven efficacy in animal models of IE successful prophylaxis does not require bactericidal antibiotics Antiseptic mouth rinses applied immediately prior to dental procedures may reduce the incidence or magnitude of bacteremia Cover most probable pathogens circulating in the blood during a given procedure identification of patients at risk; determination of the procedures or circumstances that may result in bacteremias; choice of an appropriate antimicrobial regimen; and balancing of the known risks against the possible benefits of intervention. oropharyngeal manipulation-streptococci gastrointestinal or urogenital manipulations, it should be aimed at enterococci (plus results of a preprocedure urine culture) skin or other infected lesions-staphylococci If already on antibiotics, choose another class. Cardiac Conditions Associated With Endocarditis Endocarditis prophylaxis recommended High-risk category Prosthetic cardiac valves, including bioprosthetic and homograft valves Previous bacterial endocarditis Complex cyanotic congenital heart disease (eg, single ventricle states, transposition of the great arteries, tetralogy of Fallot) Surgically constructed systemic pulmonary shunts or conduits Moderate-risk category Most other congenital cardiac malformations (other than above and below) Acquired valvar dysfunction (eg, rheumatic heart disease) Hypertrophic cardiomyopathy Mitral valve prolapse with valvar regurgitation and/or thickened leaflets1 Endocarditis prophylaxis not recommended Negligible-risk category (no greater risk than the general population) Isolated secundum atrial septal defect Surgical repair of atrial septal defect, ventricular septal defect, or patent ductus arteriosus (without residua beyond 6 mo) Previous coronary artery bypass graft surgery Mitral valve prolapse without valvar regurgitation (risk only increased if prolapse and regurg) Physiologic, functional, or innocent heart murmurs1 Previous Kawasaki disease without valvar dysfunction Previous rheumatic fever without valvar dysfunction Cardiac pacemakers (intravascular and epicardial) and implanted defibrillators AHA, 1997 Diagnosis Duke criteria Classic exam/lab findings Osler nodes Splenomegaly Janeway lesions Microscopic hematuria Elevated ESR and CRP Septic pulmonary emboli (right) Classic findings may be absent Repeating TEE 7 to 10 days after an initial "negative" result may be advisable Posttreatment echocardiography is recommended Peripheral Stigmata of IE Osler node=small, raised, tender cutaneous lesion, usually on the pads of fingers or toes (vasculitic) Janeway lesion=flat, painless small hemorrhages with a slightly nodular appearance that occur on the palms and soles (septic emboli) Splinter hemorrhages Petechiae Roth spots=hemorrhage in the retina with a white center Definite infective endocarditis Pathological criteria Microorganisms demonstrated by culture or histological examination of a vegetation, a vegetation that has embolized, or an intracardiac abscess specimen Pathological lesions; vegetation or intracardiac abscess confirmed by histological examination showing active endocarditis Clinical criteria 2 major criteria; or 1 major criterion and 3 minor criteria; or 5 minor criteria Possible IE 1 major criterion and 1 minor criterion; or 3 minor criteria Rejected Firm alternative diagnosis explaining evidence of IE; or Resolution of IE syndrome with antibiotic therapy for <4 days; or No pathological evidence of IE at surgery or autopsy, with antibiotic therapy for <4 days; or Does not meet criteria for possible IE as above Major criteria Blood culture positive for IE Typical microorganisms consistent with IE from 2 separate blood cultures: Viridans streptococci, Streptococcus bovis, HACEK group, Staphylococcus aureus; or communityacquired enterococci in the absence of a primary focus; or Microorganisms consistent with IE from persistently positive blood cultures defined as follows: At least 2 positive cultures of blood samples drawn >12 h apart; or all of 3 or a majority of 4 separate cultures of blood (with first and last sample drawn at least 1 h apart) Single positive blood culture for Coxiella burnetii or anti–phase 1 IgG antibody titer >1:800 Evidence of endocardial involvement Echocardiogram positive for IE: defined as follows: oscillating intracardiac mass on valve or supporting structures, in the path of regurgitant jets, or on implanted material in the absence of an alternative anatomic explanation; or abscess; or new partial dehiscence of prosthetic valve; new valvular regurgitation (worsening or changing or preexisting murmur not sufficient) Minor criteria Predisposition, predisposing heart condition, or IDU Fever, temperature >38°C Vascular phenomena, major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, and Janeway’s lesions Immunologic phenomena: glomerulonephritis, Osler’s nodes, Roth’s spots, and rheumatoid factor Microbiological evidence: positive blood culture but does not meet a major criterion as noted above* or serological evidence of active infection with organism consistent with IE Echocardiographic minor criteria eliminated Surgery Indication Severe CHF (reduced mortality with surgery) Persistent bacteremia Certain pathogens (fungal, GNR) Embolic events Large vegetation on mitral valve highest risk Valve abscess/dehiscence Timing 7-fold higher risk of recurrent IE if valve replaced during active infection Treatment If using synergistic agents give them together Day 1 is first day documented negative blood cultures postoperative treatment regimen should be one that is recommended for prosthetic valve treatment rather than one that is recommended for native valve treatment Start over if cultures positive Viridans Strep community-acquired native valve endocarditis in patients who are not intravenous drug users (IDUs). -hemolytic S sanguis, S oralis (mitis), S salivarius, S mutans, and Gemella morbillorum (formerly called S morbillorum). S anginosus group (S intermedius, anginosus, and constellatus) aka S milleri group have nutritional deficiencies that hinder their growth Gemella (morbillorum, bergeriae, sanguinis, and hemolysans) tends to form abscesses and cause hematogenously disseminated infection (eg, myocardial and visceral abscesses, septic arthritis, vertebral osteomyelitis). S intermedius usually is sensitive to penicillin, but some strains may exhibit variable penicillin resistance. Abiotrophia defectiva and Granulicatella species (G elegans, G adiacens, G paraadiacens, and G balaenopterae; formerly known as nutritionally variant streptococci), share some physiological characteristics with nutritionally variant streptococci should be treated with more aggressive combination therapy S bovis expresses the group D antigen, but it can be distinguished from group D Enterococcus by appropriate biochemical tests. should undergo colonoscopy Treatment Native valve, highly susceptible viridans Strep or Strep bovis (MIC <.12) Aq Pen G x 4 wks Rocephin x 4 wks Aq Pen G + gent x 2 wks (synergy) Rocephin + gent x 2 wks Vanc x 4 wks Viridans Group Streptococci and S bovis With Penicillin MIC >0.12 to 0.5 µg/ml Aq pen or Rocephin x 4 wks + gent 1st 2 wks (single daily dose) vancomycin Treatment A defectiva, Granulicatella species, and Gemella species and a microorganism with an MIC to penicillin >0.5 µg/mL should be treated with a regimen that is recommended for enterococcal endocarditis prosthetic valves should receive 6 weeks of therapy with penicillin or ceftriaxone with or without gentamicin for the first 2 weeks S pneumoniae, S pyogenes, and Groups B, C, and G Streptococci highly penicillin-susceptible S pneumoniae should receive 4 weeks of antimicrobial therapy with penicillin, cefazolin, or ceftriaxone High-dose penicillin or a third-generation cephalosporin can be used in patients with penicillin-resistant infection and without meningitis If the isolate is resistant (MIC 2 µg/mL) to cefotaxime, then the addition of vancomycin and rifampin should be considered. Consider gentamicin for at least the first 2 weeks of a 4- to 6-week course of antimicrobial therapy for group B, C, and G strep (relatively pen res) Aq pen G for Gp A Coagulase-negative Staph (CoNS) Usually associated with PVE Occasionally native valve, usually damaged More indolent than Staph aureus Staph lugdinensis more virulent Staph aureus endocarditis Nosocomial bacteremia previously thought to be lower risk for endocarditis health care–associated infection was the single most common form of S aureus IE health care–associated IE is distinguished by a relative infrequency of classic clinical stigmata of IE S aureus bacteremia associated with health care has increased among hospitalized patients and among those receiving outpatient medical therapy MRSA in both hospital and community increased dramatically implanted medical devices prosthetic heart valves grafts hemodialysis catheters pacemakers Endocarditis Factors associated with Staph aureus SBE: Native valve Hemodialysis Invasive procedures Other chronic disease Multiple pulmonary emboli Intravascular device source Tricuspid Healthcare-associated IDU-associated Persistent bacteremia, emboli requiring surgery Complications including stroke, other emboli, death Factors associated with non-Staph aureus SBE Aortic valve Prosthetic valve Congenital heart disease Dental work Symptoms >1 month International Collaboration on Endocarditis-Prospective Cohort Study from June 2000 to December 2003. Figure. In-Hospital Mortality Rates Among Patients With Health Care–Associated Staphylococcus aureus Endocarditis. Includes both nosocomial and nonnosocomial health care–associated infections, community-acquired injection drug use–associated S aureus endocarditis, and community-acquired noninjection drug use–associated S aureus endocarditis by geographic region. From: Fowler: JAMA, Volume 293(24).June 22/29, 2005.3012–3021 Table 4. Clinical Characteristics and Outcomes of 424 Prospectively Identified Patients With Definite Endocarditis Due to Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus* From: Fowler: JAMA, Volume 293(24).June 22/29, 2005.3012–3021 Treatment Staph aureus IDU (right) parenteral ß-lactam +/- gent x 2 wks (uncomplicated) Oral also effective (Cipro + rifampin x 4 wks) Vancomycin requires 4 wks Staph aureus non-IDU Beta lactam x 4-6wks, gent 1st few days if fulminant Faster clearance of bacteremia Not better mortality Vanc only if anaphylactoid history to PEN Clinda not recommended, high relapse rate Consider desensitizing or daptomycin. PVE add gentamicin for 2 wks, plus rifampin full 6 wks Treatment MRSA Vancomycin (same gent caveats, plus possible increased ototox) Linezolid Synercid Daptomycin PVE add gentamicin for 2 wks, plus rifampin full 6 wks CoNS Assume meth-resistant Vancomycin for 6 wks PVE add gentamicin for 2 wks, plus rifampin full 6 wks Enterococci Group D test MICs to penicillin and vancomycin and for high-level resistance to gentamicin and streptomycin trough antibiotic concentration in serum must be maintained above the MIC. relatively resistant to penicillin, ampicillin, and vancomycin. requires the synergistic action of penicillin, ampicillin, or vancomycin in combination with either gentamicin or streptomycin. relatively impermeable to aminoglycosides. cell wall–active agents raise the permeability of the enterococcal cell so that a bactericidal effect can be achieved If resistant to high concentrations of an aminoglycoside (500 µg/mL of gentamicin or 1000 µg/mL of streptomycin), then the combination of an aminoglycoside with the cell wall–active agent will not result in bactericidal activity, nor will it predictably produce a microbiological cure. <3 months’ duration of symptoms 4 weeks; >3 months’ duration of symptoms 6 weeks PVE 6 wks Enterococci Beta lactam resistant-vancomycin VRE vancomycin-resistant E faecalis and E gallinarum/casseliflavus usually are penicillin susceptible Linezolid Daptomycin Synercid (faecium only) HACEK fastidious Gram-negative bacilli (grow slowly ) Haemophilus parainfluenzae, H aphrophilus, H paraphrophilus, H influenzae, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae, and K denitrificans 5%-10% of native valve community-acquired IE in non IDUs hold blood cultures for 2 wks in patients suspected of having IE. ß-lactamase–producing strains increasing should be considered ampicillin resistant susceptible to ceftriaxone, ampicillin-sulbactam, and fluoroquinolones. limited published clinical data duration of therapy for native valve infection should be 4 weeks prosthetic valve 6 weeks bacteremia caused by HACEK is highly suggestive of endocarditis Other Gram-negatives IDU, prosthetic valve, and cirrhosis are risk factors Enterobacteriaceae Salmonella species have an affinity for abnormal cardiac valves Valvular perforation, atrial thrombi, myocarditis, and pericarditis are common Salmonellae also may produce endarteritis in aneurysms of major vessels. Other Enterobacteriaceae, including E coli and Serratia marcescens, may rarely cause endocarditis S marcescens endocarditis typically develops in IDUs. Left-sided disease, large vegetations, and involvement of normal valves mortality rates are 70%. Cardiac surgery is a cornerstone of treatment Combinations of pens/cephs and aminoglycosides have been shown to be synergistic E. coli or Proteus mirabilis, a combination of either ampicillin or penicillin or a broad-spectrum ceph + aminoglycoside, usually gent Endovascular Salmonella infections also may respond to third-generation cephalosporins. combination of a thirdgeneration cephalosporin and an aminoglycoside (either gentamicin or amikacin) is recommended for Klebsiella endocarditis. Pseudomonas Nearly all IDUs Associated with tripelennamine and pentazocine ("T’s and blues") mean age 30 years affects normal valves Major embolic phenomena, inability to sterilize valves, neurol complications (53%), ring and annular abscesses, splenic abscesses, bacteremic relapses, and rapidly progressive CHF are common. many authorities recommend early surgery for left-sided Pseudomonas endocarditis High-dose regimens of antipseudomonal penicillins combined with aminoglycosides are used minimum 6 weeks Medical therapy works in P aeruginosa IE involving the right side of the heart in 50% to 75% partial tricuspid valvulectomy or "vegetectomy“ if failure quinolones (in combination with an aminoglycoside) appear promising, based on favorable results in animal models and humans, but development of stepwise resistance during therapy may limit the efficacy ceftazidime-tobramycin is preferred over aztreonamtobramycin 7 cases of P aeruginosa endocarditis have been successfully treated with imipenem plus an aminoglycoside potential for the development of resistance exists with any of these regimens. Culture-negative IE Why? Antibiotics prior Fastidious organism (Rocephin + gent +doxy) Cover your bases i.e. Staph, Strep, enterococcus Bartonella Brucella Q fever Whipple’s Chlamydia Not infectious Marantic Autoimmune Neoplastic Fungal IE often a complication of medical and surgical advances usually have multiple predisposing conditions (cardiovascular devices, prosthetic cardiac valves and central venous catheters) mortality rates for fungal endocarditis are very high. survival rate for patients with mold-related endocarditis is <20%. Candida and Aspergillus species account for the large majority Historically, is an indication for surgical replacement of an infected valve. amphotericin B, a fungicidal agent, is the drug of choice antifungal therapy usually is given for 6 weeks. long-term (lifelong) suppressive therapy with an oral azole Predisposing Conditions in FE From: Pierrotti: Chest, Volume 122(1).July 2002.302-310 Complications of FE From: Pierrotti: Chest, Volume 122(1).July 2002.302-310 Complications of IE Cardiovascular CHF MI Mycotic aneurysms Embolic CVA Peripheral Organ Bowel Peripheral arteries spleen